OBR and MDoutlook are pleased to share excerpts from the most recent MDoutlook OncoPolls™ following this year’s ASCO annual meeting in Chicago. This final report (from series of three releases with MDoutlook over the past week) highlights the three (3) oral presentations from Tuesday morning ASCO presentations concerning chronic lymphocytic leukemia (CLL). These presentations discussed the first-line use of Venetoclax + Obinutuzumab, the use of Acalabrutinib + Obinutuzumab in both the first-line and relapsed/refractory settings, and the CAR-T product Lisocabtagene maraleucel.
This research is based on separate, identical surveys conducted with US and EU5-based oncologists who treat CLL. The full complimentary report is available through MDoutlook.
Abstract #7502: Venetoclax plus Obinutuzumab as a 1st line treatment for CLL
Key Conclusions about Abstract #7502 (Venetoclax + Obinutuzumab in first-line CLL)
Abstract #7500: Acalabrutinib plus Obinutuzumab for 1st line CLL and r/r CLL
Key Conclusions about Abstract #7500 (Acalabrutinib + Obinutuzumab in untreated and r/r CLL)
Abstract #7501: Lisocabtagene Maraleucel (Liso-Cel) in r/r CLL
Key Conclusions about Abstract #7501 (Liso Cel in r/r CLL)
Expected Integration of New ASCO Data into Clinical Practices
Key Conclusions about Integration of New ASCO Data into Clinical Practice
Overall Conclusions: Immediate Impact of 2019 ASCO Presentations on the Clinical Practice for CLL
Submitted by Robert Stephan, SVP, Research & Operations and Jan Heybroek, President, MDoutlook.
You must be logged in to post a comment